Bloomberg -- Roche Holding AG’s Avastin failed to win the backing of the U.K. National Institute for Health and Clinical Excellence for use in combination with chemotherapy against colorectal cancer that has spread. The drug’s benefits don’t justify the cost, the agency said today in an e-mailed statement. The decision, which confirms preliminary rulings by NICE, is final, the agency said.
